Erythrocyte-endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria: Adverse effects reversed with Piracetam

R. M. Nalbandian, R. L. Henry, J. A. Fleischman, L. Burek, G. Williams, F. E. O'Donnell, C. A. Diglio, B. D. Collier, F. H. Reeser

Research output: Contribution to journalArticle

Abstract

The erythrocytes of patients with sickle hemoglobin, diabetes, and Falciparum malaria adhere disproportionately to endothelial cells. Such pathophysiological activity compromises the microcirculation and results in clinical disease. Since Piracetam (2-oxo-1 pyrrolidine acetamide) has been shown to have a number of clinically beneficial actions on the formed elements of the blood including disengagement of adherent diabetic and sickle erythrocytes there is a rational basis for the trial of Piracetam as an adjuvant drug in SS disease and in diabetes mellitus to improve function of the microcirculation. For similiar but somewhat more complex reasons Piracetam may potentiate the efficacy of anti-malarial drugs at any given dosage. Piracetam, a drug known to be safe in a decade of clinical usage, merits serious study in the 3 cited diseases.

Original languageEnglish (US)
Pages (from-to)155-162
Number of pages8
JournalMedical Hypotheses
Volume8
Issue number2
DOIs
StatePublished - 1982
Externally publishedYes

Fingerprint

Piracetam
Falciparum Malaria
Sickle Cell Anemia
Diabetes Mellitus
Endothelial Cells
Erythrocytes
Microcirculation
Pharmaceutical Preparations
Sickle Hemoglobin
Antimalarials

ASJC Scopus subject areas

  • Developmental Biology
  • Medicine(all)
  • Drug Discovery

Cite this

Nalbandian, R. M., Henry, R. L., Fleischman, J. A., Burek, L., Williams, G., O'Donnell, F. E., ... Reeser, F. H. (1982). Erythrocyte-endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria: Adverse effects reversed with Piracetam. Medical Hypotheses, 8(2), 155-162. https://doi.org/10.1016/0306-9877(82)90098-6

Erythrocyte-endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria : Adverse effects reversed with Piracetam. / Nalbandian, R. M.; Henry, R. L.; Fleischman, J. A.; Burek, L.; Williams, G.; O'Donnell, F. E.; Diglio, C. A.; Collier, B. D.; Reeser, F. H.

In: Medical Hypotheses, Vol. 8, No. 2, 1982, p. 155-162.

Research output: Contribution to journalArticle

Nalbandian, RM, Henry, RL, Fleischman, JA, Burek, L, Williams, G, O'Donnell, FE, Diglio, CA, Collier, BD & Reeser, FH 1982, 'Erythrocyte-endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria: Adverse effects reversed with Piracetam', Medical Hypotheses, vol. 8, no. 2, pp. 155-162. https://doi.org/10.1016/0306-9877(82)90098-6
Nalbandian, R. M. ; Henry, R. L. ; Fleischman, J. A. ; Burek, L. ; Williams, G. ; O'Donnell, F. E. ; Diglio, C. A. ; Collier, B. D. ; Reeser, F. H. / Erythrocyte-endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria : Adverse effects reversed with Piracetam. In: Medical Hypotheses. 1982 ; Vol. 8, No. 2. pp. 155-162.
@article{f6f4f2721e734242869929a3dc7a0f27,
title = "Erythrocyte-endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria: Adverse effects reversed with Piracetam",
abstract = "The erythrocytes of patients with sickle hemoglobin, diabetes, and Falciparum malaria adhere disproportionately to endothelial cells. Such pathophysiological activity compromises the microcirculation and results in clinical disease. Since Piracetam (2-oxo-1 pyrrolidine acetamide) has been shown to have a number of clinically beneficial actions on the formed elements of the blood including disengagement of adherent diabetic and sickle erythrocytes there is a rational basis for the trial of Piracetam as an adjuvant drug in SS disease and in diabetes mellitus to improve function of the microcirculation. For similiar but somewhat more complex reasons Piracetam may potentiate the efficacy of anti-malarial drugs at any given dosage. Piracetam, a drug known to be safe in a decade of clinical usage, merits serious study in the 3 cited diseases.",
author = "Nalbandian, {R. M.} and Henry, {R. L.} and Fleischman, {J. A.} and L. Burek and G. Williams and O'Donnell, {F. E.} and Diglio, {C. A.} and Collier, {B. D.} and Reeser, {F. H.}",
year = "1982",
doi = "10.1016/0306-9877(82)90098-6",
language = "English (US)",
volume = "8",
pages = "155--162",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Erythrocyte-endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria

T2 - Adverse effects reversed with Piracetam

AU - Nalbandian, R. M.

AU - Henry, R. L.

AU - Fleischman, J. A.

AU - Burek, L.

AU - Williams, G.

AU - O'Donnell, F. E.

AU - Diglio, C. A.

AU - Collier, B. D.

AU - Reeser, F. H.

PY - 1982

Y1 - 1982

N2 - The erythrocytes of patients with sickle hemoglobin, diabetes, and Falciparum malaria adhere disproportionately to endothelial cells. Such pathophysiological activity compromises the microcirculation and results in clinical disease. Since Piracetam (2-oxo-1 pyrrolidine acetamide) has been shown to have a number of clinically beneficial actions on the formed elements of the blood including disengagement of adherent diabetic and sickle erythrocytes there is a rational basis for the trial of Piracetam as an adjuvant drug in SS disease and in diabetes mellitus to improve function of the microcirculation. For similiar but somewhat more complex reasons Piracetam may potentiate the efficacy of anti-malarial drugs at any given dosage. Piracetam, a drug known to be safe in a decade of clinical usage, merits serious study in the 3 cited diseases.

AB - The erythrocytes of patients with sickle hemoglobin, diabetes, and Falciparum malaria adhere disproportionately to endothelial cells. Such pathophysiological activity compromises the microcirculation and results in clinical disease. Since Piracetam (2-oxo-1 pyrrolidine acetamide) has been shown to have a number of clinically beneficial actions on the formed elements of the blood including disengagement of adherent diabetic and sickle erythrocytes there is a rational basis for the trial of Piracetam as an adjuvant drug in SS disease and in diabetes mellitus to improve function of the microcirculation. For similiar but somewhat more complex reasons Piracetam may potentiate the efficacy of anti-malarial drugs at any given dosage. Piracetam, a drug known to be safe in a decade of clinical usage, merits serious study in the 3 cited diseases.

UR - http://www.scopus.com/inward/record.url?scp=0019998063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019998063&partnerID=8YFLogxK

U2 - 10.1016/0306-9877(82)90098-6

DO - 10.1016/0306-9877(82)90098-6

M3 - Article

C2 - 7045599

AN - SCOPUS:0019998063

VL - 8

SP - 155

EP - 162

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 2

ER -